New Drug Development Paradigms in China: Simultaneous Global Drug Development Program

2012 ◽  
Vol 22 (5) ◽  
pp. 1060-1073 ◽  
Author(s):  
Qin Huang ◽  
Gang Chen ◽  
Zhilong Yuan ◽  
K. K. Gordon Lan

2000 ◽  
Vol 2 (3) ◽  
pp. 213-217

Working closely and cooperatively with regulatory authorities during drug development is vital to successful drug development programs. In the United States, the drug development team includes not only members of the key disciplines of drug discovery, clinical research, regulatory affairs, marketing, chemistry, toxicology, and legal aspects, but also the Food and Drug Administration (FDA). New regulations encourage meetings at the pre-investigational new drug (pre-IND), end-of-phase-2, and pre-new drug application (pre-NDA) submission phases. Appropriate informal discussions via fax and telephone are also encouraged. By proactively interacting with the FDA, the pharmaceutical industry increases the probability of a successful drug development program.


2017 ◽  
Vol 27 (6) ◽  
pp. 945-962
Author(s):  
William Wang ◽  
Zhiwei Jiang ◽  
Jingjun Qiu ◽  
Jielai Xia ◽  
Xiang Guo

2014 ◽  
Vol 25 (6) ◽  
pp. 1135-1144 ◽  
Author(s):  
Kezhen Liu ◽  
Zhilong Yuan ◽  
Gang Chen ◽  
Qin Huang ◽  
Judith Wenrich

2014 ◽  
Vol 15 (1) ◽  
pp. 283-306
Author(s):  
Kim, Chang Won ◽  
Lee Cheol-Gyu ◽  
Youn Sung Kim ◽  
WangJin Yoo

2011 ◽  
Vol 22 ◽  
pp. ii54-ii57

Sign in / Sign up

Export Citation Format

Share Document